Integrating AI Discovery, Continuous Manufacturing, and Modern Regulatory Hurdles into Pharma Production

Laine Mello, director of Marketing at Ecolab Life Sciences, discusses how AI and Pharma 4.0 are fundamentally reshaping the pharmaceutical landscape in this part 2 of a 3-part interview (check out part 1 and part 3). Drawing on a decade of industry experience, Mello explores the transition from traditional batch production to high-efficiency, digitally driven bioprocessing.

The most immediate impact of AI is felt in the research phase, where the timeline for designing molecules has shrunk from months to weeks. Mello emphasizes the magnitude of this shift, stating, AI “is fundamentally changing the timeline for drug discovery, which I think we’re…